Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with China-based Beijing Aosaikang Pharmaceutical (ASK Pharm) covers China, Hong Kong, Macau and Taiwan. ASK Pharm will complete any required clinical trials in China and file the marketing authorisation for the treatment of iron deficiency in all territories covered by the deal; we forecast China launch in 2023. Shield will receive an upfront licen
13 Jan 2020
Shield Therapeutics - Feraccru out-licensed in China
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Feraccru out-licensed in China
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.8m
- Published:
13 Jan 2020 -
Author:
Dr Susie Jana -
Pages:
5
Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with China-based Beijing Aosaikang Pharmaceutical (ASK Pharm) covers China, Hong Kong, Macau and Taiwan. ASK Pharm will complete any required clinical trials in China and file the marketing authorisation for the treatment of iron deficiency in all territories covered by the deal; we forecast China launch in 2023. Shield will receive an upfront licen